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INTRODUCTION
Autologous hematopoietic cell transplantation (AHCT) is
a frequently used treatment modality for children and adult
patients with hematologic malignancies and selected solid
tumors. The conditions for which AHCT has been employed
successfully are listed in Table 1. Note that “clinical use” is
not synonymous with “established superior therapy.”
In the United States, approximately 14,000 patients
were treated with AHCT during the year 2000 (M.M.
Horowitz, MD, oral communication, 2001). In other parts
of the world where AHCT is offered to cancer patients, a
similar number of patients received this treatment, accord-
ing to this author’s estimate, so that last year the total num-
ber of AHCT recipients ranged from 25,000 to 35,000.
Published data from numerous transplantation centers
indicate that long-term disease-free survival (DFS) rates vary
from approximately 20% to more than 80% depending on
the patient’s remission status at the time when preparation
for AHCT is begun. Relapse of the underlying disease is the
major source of treatment failure. The clinical use of AHCT
with all of its potential risks and side effects is justiﬁed only
when 3 conditions are met: that the overall treatment
approach is optimized, that patients receive treatment
according to clinical research protocols, and that outcome
data are reported in the scientiﬁc literature and/or to orga-
nized transplantation registries (Autologous Bone Marrow
Transplant Registry in the United States [ABMT], European
Group for Blood and Marrow Transplantation [EBMT]).
Several opportunities that either singly or in combina-
tion can contribute to improved outcome results of AHCT
are listed in Table 2. The following discussion is intended to
demonstrate that advances made through successful transla-
tional research have led to favorable results in the area of
AHCT, with treatment of non-Hodgkin’s lymphoma (NHL)
serving as an example.
TIMING OF AHCT WITH RESPECT TO REMISSION STATUS
The amount of tumor burden is indirectly propor-
tional to long-term DFS. Another factor contributing to
treatment failure (relapse) is drug resistance of malig-
nant cells. Therefore, AHCT during first remission of a
disease such as follicular lymphoma is likely to be more
successful than AHCT during subsequent remissions [1-3].
In a prospective phase II trial performed from 1988 to
1994, we studied 37 eligible adult patients with previ-
ously untreated stage III or IV follicular NHL [4].
After the patients achieved a state of minimal residual
disease (MRD) with standard-dose chemotherapy, bone mar-
row was obtained under general anesthesia and treated
with a combination of monoclonal antibodies (MoAbs)
directed against B-cell epitopes and complement followed
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Table 1. Clinical Use of Autologous Hematopoietic Cell Transplantation
Acute leukemia (myelogenous, lymphoblastic)
Chronic lymphocytic leukemia
Non-Hodgkin’s lymphoma
Multiple myeloma
Neuroblastoma and other selected pediatric tumors
Solid tumors in adult patients (breast cancer, ovarian cancer, 
testicular cancer)
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by cryopreservation. Patients were exposed to a high-
dose preparatory regimen that consisted of fractionated
total body irradiation (FTBI), etoposide (VP-16), and
cyclophosphamide (CY) with subsequent autografting.
After an observation time of 6 to 12 years, the disease-spe-
cific survival rate was 97%; 32 (86%) of the 37 enrolled
patients were alive; and 23 patients (62%) were in contin-
ued complete remission, whereas the actuarial relapse rate
was 30% (Figure 1). It appears that the natural history of
follicular lymphoma has been successfully altered, result-
ing in excellent overall survival (OS) and DFS rates. In
contrast, 66 patients with either recurrent or transformed
follicular lymphoma treated at our center with myeloabla-
tive therapies and AHCT (MoAb-purged bone marrow or
peripheral blood cell grafts) attained clearly less favorable
OS (52%) and DFS (41%) rates [5].
SELECTION OF MYELOABLATIVE DOSAGE AND
COMBINATIONS OF DRUGS WITH OR WITHOUT
IRRADIATION
The sole purpose of the preparatory regimen admin-
istered before AHCT is to eradicate the underlying dis-
eases by destroying—ideally—all malignant cells. Dose
escalation studies of drugs and drug combinations have
led to regimens that have proven to be potent and effec-
tive against lymphoid malignancies, in particular NHL.
We have employed a triple combination of FTBI, VP-16,
and CY at maximum tolerated doses (MTD) for patients
younger than 60 years who had not been previously
treated with irradiation [6]. For patients older than 60
years or patients who had received prior radiotherapy,
FTBI was replaced by 1,3-bis(2-chloroethyl)-1-
nitrosourea (BCNU) at MTD [6]. Since the inception of
our program in 1987, a total of 439 patients with persis-
tent or relapsed NHL have received 1 of these 2 prepara-
tory regimens. Actuarial survival and relapse data are pre-
sented in Figure 2A and B.
It is noteworthy that the FTBI-containing regimen was
more toxic during the early posttransplantation phase but
still led to improved long-term OS rates. In particular, radi-
ation was not associated with an increased incidence of sec-
ond or secondary malignancies after AHCT. The 2 relapse
curves are virtually superimposable, conﬁrming our earlier
reported observations [7].
A different and potentially more successful approach
was chosen by investigators at the University of Washington
[8]. They replaced FTBI with radiolabeled MoAbs directed
against CD20 to deliver radiation targeted to tumor sites
and attained promising results in a clinical phase I/II trial.
Two other studies employing the same treatment principle
are underway at the City of Hope National Medical Center
(S.J. Forman, MD, written communication, 1999) and at the
University of Nebraska (J.M. Vose, MD, written communi-
cation, 2001).
Figure 1. Actuarial disease-speciﬁc survival (DSS), overall survival (OS), disease-free survival (DFS), and relapse (REL) following autologous bone mar-
row transplantation in 37 patients with follicular lymphoma during their ﬁrst complete (n = 8) or ﬁrst partial (n = 29) chemotherapy-induced remissions.
Table 2. Opportunities to Improve the Outcome of Autologous Hematopoietic
Cell Transplantation (AHCT)
Timing of AHCT with respect to remission status
Selection of myeloablative doses and combinations of drugs with or 
without irradiation
Optimizing the graft, ie, removal of clonogenic tumors without loss 
of activity for hematopoietic reconstitution
Post-AHCT therapy to consolidate remission (cytokines, monoclonal 
antibodies, vaccines, cells, involved-field radiation)
Table 3. Problem Areas of Autologous Hematopoietic Cell Transplantation*
Age limit
Regimen-related toxicity
Graft failure
Opportunistic infections
Relapse
Secondary and second malignancies
Quality of life
Cost/charges
*Problems are listed in chronological order as they occur during the
course of an autologous transplantation procedure. The main problem
is relapse of the underlying cancer.
OPTIMIZING THE GRAFT: REMOVAL OF CLONOGENIC
TUMOR CELLS WITHOUT LOSS OF ACTIVITY FOR
HEMATOPOIETIC RECONSTITUTION
Ten years ago, investigators at the Dana Farber Cancer
Institute demonstrated that patients with NHL who received
autologous marrow grafts devoid of even the smallest num-
ber of detectable tumor cells (as demonstrated by polymerase
chain reaction [PCR]) attained statistically superior DFS
rates compared with patients whose grafts remained PCR
positive for tumor cells after the purging process [9]. During
the past decade, bone marrow has been almost completely
replaced by peripheral blood as the source for hematopoietic
cells. Because of high total nucleated cell quantities in
apheresis products, new technical approaches were needed to
successfully remove tumor cells without loss of activity for
hematopoietic reconstitution. A 2-step method has been
developed at our center: in the ﬁrst step, a large amount of
undesired cells (about 80%) is removed by centrifugation
over percoll with a yield of approximately 80% CD34+ cells;
during the second step, lymphoma cells are removed by
MoAb/complement lysis [10]. A survival analysis of 439
patients with either persistent or relapsed NHL is shown in
Figure 3. A total of 148 patients received grafts of MoAb-
purged marrow cells and 291 patients received MoAb-
purged blood cells. There was a trend (P = .07) toward
improved OS rates in patients who received blood-cell grafts
compared with those who received marrow-cell grafts.
Of note, patients with NHL who do not “mobilize” CD34+
cells adequately into the blood can still successfully undergo
AHCT using marrow-derived MoAb-purged grafts [11].
Recent reports indicate that systemic administration of
the MoAb directed against the CD20 epitope can lead to
successful in vivo purging of CD34-cell–enriched peripheral
blood harvests [12,13].
Positive selection of hematopoietic stem cells is
another conceptually attractive, albeit technically demand-
ing, approach to attaining tumor-free autologous grafts
[14]. This method may play an important future role in
AHCT, especially after being simplified and becoming
more widely available.
POSTTRANSPLANTATION THERAPY TO CONSOLIDATE
REMISSION
Many patients with NHL and other diseases enter a com-
plete remission or MRD state. Such favorable clinical condi-
tions provide an opportunity for consolidation strategies
using cytokines, MoAbs, vaccines, specifically engineered
cells, local irradiation, posttransplantation chemotherapy, or a
combination of several of these modalities.
Cytokines 
A combination of interferon and interleukin-2 (IL-2) was
administered to 56 NHL patients after AHCT [15]. DFS and
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Figure 2. Effect of 2 preparatory regimens (fractionated total body irradiation [FTBI]/etoposide [VP-16]/cyclophosphamide [CY], n = 155 and 1,3-
bis[2-chloroethyl]-1-nitrosourea [BCNU]/VP-16/CY, n = 284) on actuarial overall survival (OS) (A) and relapse (B) following autologous hemato-
poietic cell transplantation in 439 patients with persistent or recurrent non-Hodgkin’s lymphoma.
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OS rates of these patients were signiﬁcantly improved com-
pared with a group of matched historical control patients. A
phase III trial to prospectively evaluate this post-
transplantation strategy is currently being performed by
EBMT. In another trial, the Southwest Oncology Group
(SWOG) is testing posttransplantation administration of IL-2
in a randomized fashion, with patients assigned to observation
serving as controls (SWOG trial 9438). So far, IL-2 has been
reasonably well tolerated with no mortality encountered in
relation to the administration of this agent. Accrual to this
study should be completed by the end of 2001.
Monoclonal Antibodies
The posttransplantation use of MoAbs has become pos-
sible during recent years. Two groups of investigators have
explored the chimeric antibody directed against CD20, rit-
uximab [13,16]. A group of investigators at Johns Hopkins
University tested the antibody in 25 patients during the
graft mobilization phase and again after AHCT, and we
administered the MoAb twice to 35 patients with NHL in
4-week courses beginning on day 42 posttransplantation and
again on day 180. The data from both trials are sufﬁciently
promising in terms of in vivo purging effect and freedom
from relapse following AHCT, so that a phase III trial is
being initiated (under the auspices of the Eastern Coopera-
tive Oncology Group, ECOG trial E2499).
Vaccines 
Vaccination with the idiotype protein derived from
B-cell malignancies can produce idiotype-specific immune
responses that correlate with improved remission duration
and survival in patients with follicular NHL [17]. A recently
completed study at Stanford University indicates that, of
13 AHCT recipients, 11 were able to mount a strong and
speciﬁc immune response to idiotype vaccines and 8 experi-
enced prolonged remissions lasting from 3 to 11 years (T.A.
Davis, F.J. Hsu, C.B. Caspar, et al., unpublished data, 2001).
An extended prospective clinical trial is currently being per-
formed at the University of Nebraska (J.M. Vose, MD, writ-
ten communication, 2001).
Cells 
Lymphokine-activated killer cells have been tested with
and without IL-2 against a number of hematologic malig-
nancies and solid tumors. In addition to being ineffective in
NHL, this treatment was associated with rather extensive
toxicities. In contrast, cytokine-induced killer (CIK) cells
were well tolerated and led to tumor reductions in a group
of patients who had suffered relapses of their diseases after
AHCT (R. S. Negrin, MD, unpublished data, 2001). It is
now planned to test the effect of CIK cells administered
electively after AHCT to patients who are at MRD and who
have a high risk of relapse.
Irradiation 
Posttransplantation irradiation to areas of prior “bulk”
disease is a successful treatment concept for patients with
Hodgkin’s disease [18,19]. In our experience, a similarly
positive effect can be attained in the setting of AHCT for
patients with NHL (R. T. Hoppe, MD, unpublished data,
2001).
CONCLUDING REMARKS
The title I have chosen for this presentation is meant as
an imperative (hence, the exclamation mark). High-dose
combination therapy followed by a so-called “stem cell
transplant” is too often an unsuccessful answer to the difﬁ-
cult problems of cancer. It is our responsibility as physicians
and clinical investigators to employ all possible methods to
achieve an optimal and, it is hoped, a durable response.
With “cure” being the ultimate treatment goal for all
patients who come to receive AHCT, we need to use all
means to improve the outcome of our efforts. Only through
continued bench-to-bedside research will new treatment
concepts become available. Carefully designed clinical trials
are required to prove the therapeutic potential of these
novel approaches.
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